Directed by Congress to rapidly develop a list of broad-basedpriorities for the Department of Health and Human Services (DHHS)to consider as it implements a new agenda for comparative-effectivenessresearch (CER), the Institute of Medicine (IOM) released a reportrecommending a portfolio of 100 study topics related to a rangeof diseases, research methods, and care models that are importantto the health of the U.S. population. The IOM report,1 releasedJune 30, also recommends research studies on rare diseases thatdisproportionately affect certain subgroups of the population,such as women, racial or ethnic minorities, and particular agegroups. . . . [Full Text of this Article]
Source Information
Mr. Iglehart is a national correspondent for the Journal.
This article (10.1056/NEJMp0904133) was published on June 30, 2009, at NEJM.org.
This article has been cited by other articles:
Dhruva, S. S., Bero, L. A., Redberg, R. F.
(2009). Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices. JAMA
302: 2679-2685
[Abstract][Full Text]
Pandharipande, P. V., Gazelle, G. S.
(2009). Comparative Effectiveness Research: What It Means for Radiology. Radiology
253: 600-605
[Full Text]
Morris, P. E., Munro, C. L.
(2009). Will Comparative Effectiveness Research Increase Patient Safety in Intensive Care Units?. Am J Crit Care
18: 504-506
[Full Text]
Levy, A., Harrigan, B., Johnston, K., Briggs, A.
(2009). Comparative Effectiveness Research Through the Looking Glass. Med Decis Making
29: NP6-NP8
[Abstract]
